Ozempic / Mounjaro vs Generic Peptides

Ozempic and Wegovy are brand-name semaglutide made by Novo Nordisk. Mounjaro and Zepbound are brand-name tirzepatide made by Eli Lilly. These are FDA-approved, pharmaceutical-grade formulations sold through licensed pharmacies at significant cost (USD 800–1,200/month without insurance in the US).

Generic or research-grade versions contain the identical active molecule — the same amino acid sequence and chemical structure. The difference lies in manufacturing standards, inactive ingredients (excipients), and the regulatory oversight applied during production.

Generic research-grade peptides can be safe when sourced from a reputable supplier with third-party COA verification. The key risks are:

• RISK-01Underdosing — vial contains less than labeled (you get no results but think it doesn't work).
• RISK-02Contamination — improper manufacturing introduces impurities.
• RISK-03Wrong compound — product is substituted or mislabeled.
• RISK-04Improper storage — degradation before you receive it.

• + PROSame molecule, same mechanism — effectiveness should be identical if properly dosed and stored.
• + PROSignificantly lower cost makes treatment accessible without insurance.
• ~ CONRequires manual reconstitution (mixing with BAC water) vs ready-to-use pen injector.
• ~ CONCOA verification is your responsibility — choose suppliers carefully.